Breaking News

VSTM

Verastem

02
Jun
02
Jun

05/10/23 H.C. Wainwright: Verastem price target lowered to $2 from $3 at H.C. Wainwright

03/29/23 Mizuho: Verastem initiated with a Neutral at Mizuho

11/07/22 H.C. Wainwright: Verastem price target lowered to $3 from $5 at H.C. Wainwright

10/05/22 BTIG: Verastem price target lowered to $5 from $8 at BTIG

Clear This Search Refresh Search

Today Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Conference/Events	Oppenheimer biotech analyst to hold a reception » 04:55 06/02/23 06/02 04:55 06/02/23 04:55 AGEN Agenus $1.59 / +0.04 (+2.58%) , CGEN Compugen $1.01 / -0.02 (-1.94%) , DAWN Day One Biopharmaceuticals $13.65 / +0.35 (+2.63%) , ERAS Erasca $2.69 / -0.025 (-0.92%) , IMRX Immuneering $9.21 / +1.54 (+20.08%) , KNTE Kinnate Biopharma $4.32 / +0.03 (+0.70%) , MRTX Mirati Therapeutics $37.00 / -0.14 (-0.38%) , RVMD Revolution Medicines $25.19 / +0.27 (+1.08%) , VIRX Viracta Therapeutics $1.40 / +0.08 (+6.06%) , ONCT Oncternal Therapeutics / + , BMEA Biomea Fusion $35.63 / +1.745 (+5.15%) , MRNA Moderna $128.53 / +0.93 (+0.73%) , REGN Regeneron $731.21 / -2.79 (-0.38%) , AZN AstraZeneca $72.85 / -0.22 (-0.30%) , GILD Gilead $76.22 / -0.735 (-0.96%) , VSTM Verastem $11.83 / -0.17 (-1.42%) , SWTX SpringsWorks Therapeutics $27.63 / +0.23 (+0.84%) Biotech Analysts… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 5th, 04:55 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options VSTM VIRX SWTX RVMD REGN ONCT MRTX MRNA KNTE IMRX GILD ERAS DAWN CGEN BMEA AZN AGEN VSTM Verastem $11.83 / -0.17 (-1.42%) 05/31/23 Verastem announces 1-for-12 reverse stock split 05/25/23 Verastem's vutometinib shows 45% response rate in recurrent ovarian cancer 04/26/23 Interim analysis of Verastem's RAMP 201 trial to be presented at ASCO 01/24/23 Verastem reports interim data from Part A of the ongoing RAMP 201 Phase 2 study VIRX Viracta Therapeutics $1.40 / +0.08 (+6.06%) 05/02/23 Viracta Therapeutics CMO Lisa Rojkjaer, M.D to depart 01/19/23 Viracta Therapeutics announces EC orphan drug designation for Nana-val 01/08/23 Viracta announces first clinical response in EBV+ solid tumor setting SWTX SpringsWorks Therapeutics $27.63 / +0.23 (+0.84%) 05/30/23 SpringsWorks Therapeutics says Phase 2 nirogacestat trial fully enrolled 04/17/23 MapKure, SpringWorks, BeiGene present data from Phase 1a/1b study of BGB-3245 02/27/23 SpringsWorks announces FDA acceptance, priority review of nirogacestat NDA 12/27/22 SpringsWorks Therapeutics completes submission of nirogacestat NDA to FDA RVMD Revolution Medicines $25.19 / +0.27 (+1.08%) 12/19/22 Revolution Medicines announces publication on design, synthesis of RMC-5552 12/07/22 Revolution to regain rights to RMC-4630 following Sanofi deal termination 12/07/22 Sanofi terminates SHP2 Inhibitor development pact with Revolution Medicines REGN Regeneron $731.21 / -2.79 (-0.38%) 05/25/23 Regeneron says updated Linvoseltamab data demonstrates durable responses 05/25/23 Regeneron reports 'positive' data from Fianlimab-Libtayo combo trial 05/21/23 Regeneron, Sanofi present Dupixent late-breaking Phase 3 COPD results 05/18/23 Sanofi 'pleased' with Supreme Court's ruling on Amgen's asserted patent claims ONCT Oncternal Therapeutics / + 04/03/23 Oncternal Therapeutics falls 41% to 46c per share after drug development halt 04/03/23 Oncternal Therapeutics trading resumes 04/03/23 Oncternal Therapeutics to resume trading at 4:30pm ET 04/03/23 Oncternal Therapeutics halts development of zilovertamab, ibrutinib combination MRTX Mirati Therapeutics $37.00 / -0.14 (-0.38%) 05/24/23 Mirati Therapeutics falls 10% after SAPPHIRE study did not meet primary endpoint 05/24/23 Mirati Therapeutics trading resumes 05/24/23 Mirati Therapeutics says SAPPHIRE study did not meet primary endpoint 05/24/23 Mirati Therapeutics trading halted, news pending MRNA Moderna $128.53 / +0.93 (+0.73%) 05/23/23 Moderna, BioNTech other Covid vaccine makers jump amid China Covid scare 05/19/23 Moderna reports interim data from Phase 1/2 trial of mRNA-3927 05/04/23 Moderna up 5% after Q1 results beat estimates 05/04/23 Moderna, Novocol Pharma enter long-term fill-finish agreement KNTE Kinnate Biopharma $4.32 / +0.03 (+0.70%) 04/17/23 Kinnate Biopharma adds two candidates to pipeline, provides cash runway guidance 04/17/23 Kinnate Biopharma announces 'positive' monotherapy dose escalation data 02/21/23 Kinnate Biopharma acquires ownership stake of Kinnjiu Biopharma for $24M 02/14/23 Kinnate Biopharma granted fast track designation for KIN-3248 from FDA IMRX Immuneering $9.21 / +1.54 (+20.08%) 04/18/23 Immuneering down 5% at $11.53 after pricing $30M stock offering 04/18/23 Immuneering announces initial Phase 1 PK, PD, safety data for IMM-1-104 03/28/23 Immuneering appoints Harold Brakewood as CBO 03/05/23 Immuneering presents preclinical data with lead program IMM-1-104 GILD Gilead $76.22 / -0.735 (-0.96%) 05/26/23 Gilead announces CHMP reccomendation for the use of Veklury 05/17/23 Gilead to present advances across its oncology pipeline at ASCO Annual Meeting 05/15/23 Arcus Biosciences jumps 2% amid expanded inflammation pact with Gilead 05/15/23 Expanded Gilead- Arcus pact may result in up to $1B in payments to Arcus ERAS Erasca $2.69 / -0.025 (-0.92%) 05/25/23 Erasca to present HERKULES-3 phase 1b data for ERAS-007 at ASCO 05/16/23 Erasca appoints Davd Chacko as CBO, Nik Chetwyn as COO 05/01/23 Erasca announces U.S. FDA granted FTD to ERAS-801 04/25/23 Erasca announces publication of clinical data on naporafenib DAWN Day One Biopharmaceuticals $13.65 / +0.35 (+2.63%) 01/08/23 Day One announces top line data from pivotal Phase 2 FIREFLY-1 trial CGEN Compugen $1.01 / -0.02 (-1.94%) 03/06/23 Compugen doses first patient in proof-of-concept study evaluating COM701 02/14/23 Compugen: Rilvegostomig expected to progress into Phase 3 this year 12/06/22 Compugen's COM701 shows durable anti-tumor activity in ovarian cancer BMEA Biomea Fusion $35.63 / +1.745 (+5.15%) 05/01/23 Biomea says FDA clearance of IND application to begin Phase I trial of BMF-500 04/19/23 Biomea Fusion to present late breaking data from Phase II trial, COVALENT-111 03/28/23 Biomea Fusion trading resumes 03/28/23 Biomea Fusion trading halted, volatility trading pause AZN AstraZeneca $72.85 / -0.22 (-0.30%) 06/01/23 AstraZeneca, Merck announce LYNPARZA + abiraterone approved for BRCAm cancer 06/01/23 Merck and AstraZeneca's Lynparza prostate cancer combination approved by FDA 06/01/23 AstraZeneca discontinues brazikumab IBD development program 05/30/23 BioLight announces joint cooperation agreement with AstraZeneca's Alexion AGEN Agenus $1.59 / +0.04 (+2.58%) 05/03/23 Agenus up 4% after FDA approves GSK's Arexvy RSV vaccine 04/26/23 Agenus to present Phase 1, Phase 2 trial data at ASCO meeting 04/17/23 Agenus receives Fast Track Designation from FDA for botensilimab, balstilimab 03/27/23 Agenus announces results from cohort in study of botensilimab with balstilimab AGEN CGEN DAWN ERAS IMRX KNTE MRTX RVMD VIRX ONCT BMEA MRNA REGN AZN GILD VSTM SWTX AGEN Agenus $1.59 / +0.04 (+2.58%) 05/25/23 EF Hutton Agenus assumed with a Buy at EF Hutton 05/09/23 H.C. Wainwright Agenus's progress continues with data presentations, says H.C. Wainwright 04/20/23 B. Riley B. Riley came away 'encouraged' on Agenus after AACR 02/28/23 H.C. Wainwright Agenus assumed with a Buy at H.C. Wainwright CGEN Compugen $1.01 / -0.02 (-1.94%) 02/08/23 Jefferies Compugen downgraded to Underperform from Hold at Jefferies 01/04/23 EF Hutton Compugen initiated with a Buy at EF Hutton 11/14/22 Oppenheimer Compugen price target lowered to $8 from $12 at Oppenheimer 08/23/22 Truist Compugen price target lowered to $4 from $14 at Truist DAWN Day One Biopharmaceuticals $13.65 / +0.35 (+2.63%) 05/01/23 Oppenheimer Day One language around NDA submission 'sounded ominous,' says Oppenheimer 05/01/23 H.C. Wainwright Day One pullback brings attractive entry point, says H.C. Wainwright 04/25/23 BofA Day One Biopharmaceuticals double downgraded at BofA on regulatory risks 04/25/23 BofA Day One Biopharmaceuticals downgraded to Underperform from Buy at BofA ERAS Erasca $2.69 / -0.025 (-0.92%) 03/29/23 Mizuho Erasca initiated with a Buy at Mizuho 02/24/23 Goldman Sachs Erasca initiated with a Buy at Goldman Sachs 02/03/23 Morgan Stanley Erasca upgraded to Overweight from Equal Weight at Morgan Stanley IMRX Immuneering $9.21 / +1.54 (+20.08%) 04/19/23 Mizuho Immuneering upgraded to Buy from Neutral at Mizuho 04/19/23 Morgan Stanley Immuneering upgraded to Equal Weight from Underweight at Morgan Stanley 04/18/23 Chardan Immuneering price target raised to $22 from $18 at Chardan 03/29/23 Mizuho Immuneering initiated with a Neutral at Mizuho KNTE Kinnate Biopharma $4.32 / +0.03 (+0.70%) 05/18/23 H.C. Wainwright Kinnate Biopharma price target lowered to $24 from $25 at H.C. Wainwright 04/20/23 H.C. Wainwright Kinnate Biopharma price target lowered to $25 from $33 at H.C. Wainwright 04/18/23 Stifel Kinnate Biopharma price target lowered to $5 from $8 at Stifel 04/18/23 Wedbush Kinnate Biopharma price target lowered to $14 from $25 at Wedbush MRTX Mirati Therapeutics $37.00 / -0.14 (-0.38%) 05/25/23 Oppenheimer Oppenheimer upgrades Mirati to Outperform with Krazati expectations reset 05/25/23 Oppenheimer Mirati Therapeutics upgraded to Outperform from Perform at Oppenheimer 05/25/23 BMO Capital Mirati Therapeutics price target lowered to $40 from $50 at BMO Capital 05/25/23 Barclays Mirati Therapeutics price target lowered to $75 from $90 at Barclays RVMD Revolution Medicines $25.19 / +0.27 (+1.08%) 05/09/23 JPMorgan Revolution Medicines price target lowered to $35 from $38 at JPMorgan 02/28/23 Needham Revolution Medicines price target raised to $38 from $32 at Needham 02/28/23 Oppenheimer Revolution Medicines price target raised to $35 from $30 at Oppenheimer 02/28/23 JPMorgan Revolution Medicines upgraded to Overweight from Neutral at JPMorgan VIRX Viracta Therapeutics $1.40 / +0.08 (+6.06%) 05/10/23 H.C. Wainwright Viracta Therapeutics price target lowered to $33 from $35 at H.C. Wainwright ONCT Oncternal Therapeutics / + 04/06/23 Cantor Fitzgerald Oncternal downgraded to Neutral from Overweight at Cantor Fitzgerald 04/04/23 Maxim Oncternal Therapeutics downgraded to Hold from Buy at Maxim 04/04/23 Cantor Fitzgerald Oncternal Therapeutics price target lowered to $1.30 from $4.00 at Cantor Fitzgerald 04/04/23 H.C. Wainwright Oncternal Therapeutics downgraded to Neutral from Buy at H.C. Wainwright BMEA Biomea Fusion $35.63 / +1.745 (+5.15%) 05/25/23 EF Hutton Biomea Fusion assumed with a Buy at EF Hutton 05/18/23 Citi Biomea Fusion price target lowered to $53 from $55 at Citi 05/12/23 Barclays Biomea Fusion initiated with an Overweight at Barclays 04/19/23 H.C. Wainwright Biomea Fusion price target lowered to $37 from $44 at H.C. Wainwright MRNA Moderna $128.53 / +0.93 (+0.73%) 05/31/23 Jefferies Carisma Therapeutics assumed at Buy from Hold at Jefferies 05/05/23 Morgan Stanley Moderna price target lowered to $153 from $185 at Morgan Stanley 04/25/23 Guggenheim Moderna initiated with a Neutral at Guggenheim 04/13/23 Baird Carisma Therapeutics initiated with an Outperform at Baird REGN Regeneron $731.21 / -2.79 (-0.38%) 05/19/23 Piper Sandler Regeneron Q1 Eylea miss 'not about share, says Piper Sandler 05/08/23 Guggenheim Regeneron price target lowered to $935 from $960 at Guggenheim 05/05/23 Morgan Stanley Regeneron price target raised to $927 from $880 at Morgan Stanley 05/05/23 SVB Securities Regeneron price target lowered to $895 from $976 at SVB Securities AZN AstraZeneca $72.85 / -0.22 (-0.30%) 05/26/23 Argus AstraZeneca price target lowered to $80 from $85 at Argus 05/09/23 Berenberg AstraZeneca price target raised to 135 GBp from 124 GBp at Berenberg 04/28/23 JPMorgan AstraZeneca price target raised to 14,000 GBp from 13,500 GBp at JPMorgan 04/13/23 Argus AstraZeneca price target raised to $85 from $75 at Argus GILD Gilead $76.22 / -0.735 (-0.96%) 05/16/23 BMO Capital Gilead upgraded to Outperform from Market Perform at BMO Capital 04/28/23 Piper Sandler Gilead assumed with an Overweight at Piper Sandler 04/12/23 Morgan Stanley Gilead price target raised to $85 from $81 at Morgan Stanley 04/05/23 Guggenheim InflaRx upgraded to Buy at Guggenheim after Gohibic gets COVID EUA VSTM Verastem $11.83 / -0.17 (-1.42%) 05/10/23 H.C. Wainwright Verastem price target lowered to $2 from $3 at H.C. Wainwright 03/29/23 Mizuho Verastem initiated with a Neutral at Mizuho 11/07/22 H.C. Wainwright Verastem price target lowered to $3 from $5 at H.C. Wainwright 10/05/22 BTIG Verastem price target lowered to $5 from $8 at BTIG SWTX SpringsWorks Therapeutics $27.63 / +0.23 (+0.84%) 04/28/23 Barclays SpringsWorks Therapeutics price target lowered to $41 from $55 at Barclays 03/07/23 H.C. Wainwright SpringsWorks Therapeutics price target raised to $105 from $99 at H.C. Wainwright 01/02/23 Barclays Barclays views GSK acquisition interest as positive for oncology stocks 12/01/22 BofA SpringsWorks Therapeutics initiated with a Buy, $45 price target at BofA VSTM VIRX SWTX RVMD REGN ONCT MRTX MRNA KNTE GILD ERAS DAWN CGEN BMEA AZN AGEN VSTM Verastem $11.83 / -0.17 (-1.42%) 05/09/23 Verastem reports Q1 EPS (9c), consensus (8c) 03/14/23 Verastem reports Q4 EPS (8c), consensus (10c) VIRX Viracta Therapeutics $1.40 / +0.08 (+6.06%) 05/08/23 Viracta Therapeutics reports Q1 EPS (32c), consensus (31c) 03/13/23 Viracta Therapeutics reports Q4 EPS (27c), consensus (38c) SWTX SpringsWorks Therapeutics $27.63 / +0.23 (+0.84%) 05/03/23 SpringsWorks Therapeutics reports Q1 EPS ($1.18), consensus ($1.25) 02/28/23 SpringsWorks Therapeutics reports Q4 EPS ($1.19), consensus ($1.22) RVMD Revolution Medicines $25.19 / +0.27 (+1.08%) 05/08/23 Revolution Medicines reports Q1 EPS (72c), consensus (81c) 02/27/23 Revolution Medicines sees FY23 net loss $335M-$365M 02/27/23 Revolution Medicines reports Q4 EPS (63c), consensus (82c) REGN Regeneron $731.21 / -2.79 (-0.38%) 05/04/23 Regeneron reports Q1 adjusted EPS $10.09, consensus $9.56 02/03/23 Regeneron reports Q4 adjusted EPS $12.56, consensus $10.03 02/02/23 Notable companies reporting before tomorrow's open ONCT Oncternal Therapeutics / + 05/04/23 Oncternal Therapeutics reports Q1 EPS (20c), consensus (20c) MRTX Mirati Therapeutics $37.00 / -0.14 (-0.38%) 05/09/23 Mirati Therapeutics reports Q1 EPS ($3.18), consensus ($3.55) 02/28/23 Mirati Therapeutics reports Q4 EPS ($3.51), consensus ($3.55) MRNA Moderna $128.53 / +0.93 (+0.73%) 05/04/23 Moderna sees Q2 sales $200M-$300M, consensus $982.37M 02/23/23 Moderna reports Q4 EPS $3.61, consensus $4.67 02/22/23 Notable companies reporting before tomorrow's open KNTE Kinnate Biopharma $4.32 / +0.03 (+0.70%) 05/11/23 Kinnate Biopharma reports Q1 EPS (73c), consensus (73c) GILD Gilead $76.22 / -0.735 (-0.96%) 05/15/23 Gilead: Arcus deal may reduce Gilead's FY23 GAAP and non-GAAP EPS by 2c 04/27/23 Gilead backs FY23 adjusted EPS view $6.60-$7.00, consensus $6.84 04/27/23 Gilead reports Q1 Biktarvy sales up 24% y/y 04/27/23 Gilead Sciences reports Q1 adjusted EPS $1.37, consensus $1.54 ERAS Erasca $2.69 / -0.025 (-0.92%) 05/15/23 Erasca reports Q1 EPS (22c), consensus (31c) 03/23/23 Erasca reports Q4 EPS ($1.06) vs. (26c) last year DAWN Day One Biopharmaceuticals $13.65 / +0.35 (+2.63%) 05/01/23 Day One Biopharmaceuticals reports Q1 EPS (59c), consensus (59c) CGEN Compugen $1.01 / -0.02 (-1.94%) 05/15/23 Compugen reports Q1 EPS (11c), consensus (12c) 03/10/23 Compugen considers exposure to SVB Financial as immaterial 02/27/23 Compugen reports Q4 EPS (4c), consensus (14c) BMEA Biomea Fusion $35.63 / +1.745 (+5.15%) 05/02/23 Biomea Fusion reports Q1 EPS (98c), consensus (81c) 03/28/23 Biomea Fusion reports Q4 EPS (21c), consensus (81c) AZN AstraZeneca $72.85 / -0.22 (-0.30%) 04/27/23 AstraZeneca sees FY23 core EPS up high single to low double-digit percentage 04/27/23 AstraZeneca reports Q1 core EPS $1.92, consensus $1.07 02/09/23 AstraZeneca sees FY23 core EPS up high single to low double-digit percentage 02/09/23 AstraZeneca reports Q4 core EPS $1.38, consensus $1.35 AGEN Agenus $1.59 / +0.04 (+2.58%) 05/09/23 Agenus reports Q1 EPS (22c), consensus (21c) 03/14/23 Agenus reports Q4 EPS (24c), consensus (22c) 18 Apr 30 Mar 03 Mar 09 Dec 20 Jul 15 Jun REGN MRTX MRNA AZN REGN Regeneron $731.21 / -2.79 (-0.38%) 05/17/23 Regeneron CEO backs regulators attempt to block Amgen deal, FT reports MRTX Mirati Therapeutics $37.00 / -0.14 (-0.38%) 05/09/23 Boxer's Davis pitches Mirati Therapeutics as long idea at Sohn MRNA Moderna $128.53 / +0.93 (+0.73%) 05/26/23 Health authorities to target next COVID shot to new strain, WSJ says 05/23/23 China's new Covid surge could result in 65M infections a week, Bloomberg says 03/23/23 Moderna CEO defends $130 price of Covid-19 vaccine, Reuters reports 03/21/23 FDA moving towards authorizing second omicron booster, WSJ reports AZN AstraZeneca $72.85 / -0.22 (-0.30%) 05/19/23 Astra China head says company seeks to 'love the Communist Party,' Reuters says 05/04/23 AstraZeneca chair says increasing CEO's pay wards of rivals, FT reports 04/06/23 GSK unit ordered to pay AstraZeneca royalties on Zejula sales, Reuters says VSTM SWTX RVMD REGN ONCT MRTX MRNA KNTE GILD ERAS DAWN BMEA AZN AGEN VSTM Verastem $11.83 / -0.17 (-1.42%) 06/01/23 Biotech Alert: Searches spiking for these stocks today 03/14/23 Fly Intel: After-Hours Movers SWTX SpringsWorks Therapeutics $27.63 / +0.23 (+0.84%) 04/22/23 Short Report: Bears pare exposure in crypto stocks as bitcoin slumps RVMD Revolution Medicines $25.19 / +0.27 (+1.08%) 02/28/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations REGN Regeneron $731.21 / -2.79 (-0.38%) 03/28/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/27/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/24/23 What You Missed On Wall Street On Friday 03/24/23 What You Missed On Wall Street This Morning ONCT Oncternal Therapeutics / + 04/06/23 Biotech Alert: Searches spiking for these stocks today 04/04/23 Fly Intel: Pre-market Movers 04/03/23 Fly Intel: After-Hours Movers 12/07/22 Biotech Alert: Searches spiking for these stocks today MRTX Mirati Therapeutics $37.00 / -0.14 (-0.38%) 05/25/23 Fly Intel: Pre-market Movers 02/19/23 Short Report: Bearish bets in crypto arena renewed as coins and stocks rebound 12/31/22 Short Report: Bearish views reach record high on Silvergate, Mirati Therapeutics 12/16/22 Sell these stocks now, proven algorithm says MRNA Moderna $128.53 / +0.93 (+0.73%) 04/26/23 What You Missed On Wall Street On Wednesday 04/26/23 What You Missed On Wall Street This Morning 04/14/23 Biotech Alert: Searches spiking for these stocks today 04/13/23 Biotech Alert: Searches spiking for these stocks today KNTE Kinnate Biopharma $4.32 / +0.03 (+0.70%) 05/15/23 Fly Insider: Kinnate Biopharma, Arrowhead among week's notable insider trades GILD Gilead $76.22 / -0.735 (-0.96%) 05/16/23 What You Missed On Wall Street On Tuesday 05/16/23 What You Missed On Wall Street This Morning 05/16/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/28/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ERAS Erasca $2.69 / -0.025 (-0.92%) 03/23/23 Fly Intel: After-Hours Movers 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/09/22 What You Missed On Wall Street On Friday 12/09/22 What You Missed On Wall Street This Morning DAWN Day One Biopharmaceuticals $13.65 / +0.35 (+2.63%) 04/28/23 Buy/Sell: Wall Street's top 10 stock calls this week 04/25/23 What You Missed On Wall Street On Tuesday 04/25/23 What You Missed On Wall Street This Morning 04/25/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations BMEA Biomea Fusion $35.63 / +1.745 (+5.15%) 04/10/23 Fly Insider: Planet Labs, C3.ai among week's notable insider trades 03/28/23 What You Missed On Wall Street On Tuesday 03/28/23 What You Missed On Wall Street This Morning AZN AstraZeneca $72.85 / -0.22 (-0.30%) 04/11/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/05/23 What You Missed On Wall Street On Wednesday 04/05/23 What You Missed On Wall Street This Morning 02/09/23 What You Missed On Wall Street This Morning AGEN Agenus $1.59 / +0.04 (+2.58%) 04/17/23 What You Missed On Wall Street On Monday 04/17/23 What You Missed On Wall Street This Morning 01/23/23 What You Missed On Wall Street On Monday 01/23/23 What You Missed On Wall Street This Morning 18:00 Today Biotechnology--Pre-ASCO Reception 06/09/23 Biotechnology 06/12/23 Biotech/Biopharma 00:00 Today 2023 ASCO Annual Meeting 09/19/23 Institutional Investor Conference 2023 06/27/23 PDUFA Date for Eylea 08/20/23 PDUFA Date for Pozelimab 08/27/23 PDUFA Date for Nirogacestat 12/22/23 PDUFA Date for Eplontersen 06/08/23 Revolution Medicines, Inc. 06/08/23 Viracta Therapeutics Inc 06/09/23 Regeneron Pharmaceuticals 06/09/23 Kinnate Biopharma Inc. 06/12/23 Agenus Inc. 06/13/23 Compugen 06/14/23 Compugen 06/14/23 Immuneering Corp. 06/14/23 BioMea Fusion, Inc. 06/15/23 Compugen 06/22/23 Day One Biopharmaceuticals, Inc 06/22/23 Erasca, Inc. 06/28/23 Oncternal Therapeutics Inc REGN MRNA GILD BMEA AZN REGN Regeneron $731.21 / -2.79 (-0.38%) 03/23/23 Early notable gainers among liquid option names on March 23rd MRNA Moderna $128.53 / +0.93 (+0.73%) 05/24/23 Unusually active option classes on open May 24th 05/23/23 Moderna call volume above normal and directionally bullish 05/23/23 Early notable gainers among liquid option names on May 23rd 04/17/23 Unusually active option classes on open April 17th GILD Gilead $76.22 / -0.735 (-0.96%) 05/25/23 Gilead call volume above normal and directionally bullish 05/03/23 Gilead call volume above normal and directionally bullish 04/27/23 Gilead options imply 3.8% move in share price post-earnings 02/03/23 Early notable gainers among liquid option names on February 3rd BMEA Biomea Fusion $35.63 / +1.745 (+5.15%) 03/28/23 Biomea Fusion options imply 11.3% move in share price post-earnings AZN AstraZeneca $72.85 / -0.22 (-0.30%) 05/26/23 Unusually active option classes on open May 26th 05/18/23 Unusually active option classes on open May 18th 05/09/23 AstraZeneca put volume heavy and directionally bearish 04/27/23 Unusually active option classes on open April 27th

Yesterday
On The Fly	Biotech Alert: Searches spiking for these stocks today » 11:00 06/01/23 06/01 11:00 06/01/23 11:00 RVNC Revance $30.77 / +0.22 (+0.72%) , LXRX Lexicon $2.65 / -0.645 (-19.58%) , TECH Bio-Techne $81.82 / +0.05 (+0.06%) , VSTM Verastem $11.87 / -0.13 (-1.08%) , IOVA Iovance Biotherapeutics $8.99 / +0.275 (+3.16%) These names in the… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events Options VSTM TECH RVNC LXRX IOVA VSTM Verastem $11.87 / -0.13 (-1.08%) 05/31/23 Verastem announces 1-for-12 reverse stock split 05/25/23 Verastem's vutometinib shows 45% response rate in recurrent ovarian cancer 04/26/23 Interim analysis of Verastem's RAMP 201 trial to be presented at ASCO 01/24/23 Verastem reports interim data from Part A of the ongoing RAMP 201 Phase 2 study TECH Bio-Techne $81.82 / +0.05 (+0.06%) 06/01/23 Bio-Techne prevails on claim by Miltenyi Biotec 05/18/23 Bio-Techne reports interim results of ExoDx prostate cancer risk test 04/17/23 Bio-Techne, Lunaphore announce strategic partnership 03/01/23 Bio-Techne announces investment in Wilson Wolf Manufacturing RVNC Revance $30.77 / +0.22 (+0.72%) 05/09/23 Revance sees FY23 operating expenses $460M-$490M 01/10/23 Revance sees Q4 DAXXIFY revenue of $10.5M-$11.5M 01/10/23 Revance sees Q4 collection revenue at $34M-$35M 01/06/23 Revance announces FDA accepts sBLA for DAXXIFY LXRX Lexicon $2.65 / -0.645 (-19.58%) 05/26/23 Lexicon announces FDA approval of INPEFA for treatment of heart failure 05/26/23 Lexicon up 9% ahead of May 27 PDUFA action date 04/21/23 Lexicon to present results from results from RELIEF-PHN-1 trial of LX9211 03/05/23 Lexicon announces analyses of results from SOLOIST-WHF Phase 3 outcomes study IOVA Iovance Biotherapeutics $8.99 / +0.275 (+3.16%) 05/26/23 Iovance Biotherapeutics announces FDA acceptance of BLA of Lifileucel 03/24/23 Iovance Biotherapeutics completes BLA submission for lifileucel 03/10/23 Iovance says it does not hold deposits, securities at Silicon Valley Bank 01/23/23 Clinigen divests Proleukin to Iovance Biotherapeutics for GBP 166.7M RVNC LXRX TECH VSTM IOVA RVNC Revance $30.77 / +0.22 (+0.72%) 05/10/23 Piper Sandler Revance price target raised to $50 from $39 at Piper Sandler 05/10/23 H.C. Wainwright Revance price target raised to $48 from $42 at H.C. Wainwright 03/15/23 Mizuho Revance price target raised to $33 from $30 at Mizuho 03/14/23 Wells Fargo Revance price target raised to $30 from $22 at Wells Fargo LXRX Lexicon $2.65 / -0.645 (-19.58%) 05/31/23 Citi Lexicon price target raised to $8 from $6 at Citi 03/07/23 Jefferies Lexicon initiated with a Hold at Jefferies 10/03/22 Piper Sandler Lexicon remains 'significantly undervalued,' says Piper Sandler 08/29/22 Citi AstraZeneca hazard ratio notably weaker than Lexicon, says Citi TECH Bio-Techne $81.82 / +0.05 (+0.06%) 05/04/23 Baird Bio-Techne price target raised to $100 from $99 at Baird 03/09/23 Citi Citi puts 'positive catalyst watches' on three life science stocks 02/03/23 Baird Bio-Techne price target lowered to $99 from $111.50 at Baird 01/10/23 Wells Fargo Wells Fargo upgrades Bio-Techne to Equal Weight with $90 price target VSTM Verastem $11.87 / -0.13 (-1.08%) 05/10/23 H.C. Wainwright Verastem price target lowered to $2 from $3 at H.C. Wainwright 03/29/23 Mizuho Verastem initiated with a Neutral at Mizuho 11/07/22 H.C. Wainwright Verastem price target lowered to $3 from $5 at H.C. Wainwright 10/05/22 BTIG Verastem price target lowered to $5 from $8 at BTIG IOVA Iovance Biotherapeutics $8.99 / +0.275 (+3.16%) 05/30/23 Wells Fargo Iovance upgraded to Overweight at Wells Fargo after lifileucel BLA accepted 05/30/23 Wells Fargo Iovance Biotherapeutics upgraded to Overweight from Equal Weight at Wells Fargo 05/30/23 Stifel Iovance Biotherapeutics price target raised to $24 from $21 at Stifel 05/29/23 Barclays Iovance news 'important clearing event' for shares, says Barclays VSTM TECH RVNC LXRX IOVA VSTM Verastem $11.87 / -0.13 (-1.08%) 05/09/23 Verastem reports Q1 EPS (9c), consensus (8c) 03/14/23 Verastem reports Q4 EPS (8c), consensus (10c) TECH Bio-Techne $81.82 / +0.05 (+0.06%) 05/03/23 Bio-Techne reports Q3 adjusted EPS 53c, consensus 53c 02/02/23 Bio-Techne reports Q2 adjusted EPS 47c, consensus 62c RVNC Revance $30.77 / +0.22 (+0.72%) 05/09/23 Revance reports Q1 EPS (74c), consensus (70c) 02/28/23 Revance reports Q4 EPS ($1.82), consensus (95c) LXRX Lexicon $2.65 / -0.645 (-19.58%) 05/02/23 Lexicon reports Q1 EPS (17c), consensus (18c) 03/02/23 Lexicon reports Q4 EPS (16c), consensus (13c) IOVA Iovance Biotherapeutics $8.99 / +0.275 (+3.16%) 05/09/23 Iovance Biotherapeutics reports Q1 EPS (50c), consensus (74c) 02/28/23 Iovance Biotherapeutics reports Q4 EPS (64c), consensus (64c) 01 Jun 13 Sep VSTM RVNC LXRX IOVA VSTM Verastem $11.87 / -0.13 (-1.08%) 03/14/23 Fly Intel: After-Hours Movers RVNC Revance $30.77 / +0.22 (+0.72%) 06/01/23 Biotech Alert: Searches spiking for these stocks today 05/09/23 Fly Intel: After-Hours Movers 01/11/23 Biotech Alert: Searches spiking for these stocks today 01/09/23 What You Missed On Wall Street On Monday LXRX Lexicon $2.65 / -0.645 (-19.58%) 05/05/23 Biotech Alert: Searches spiking for these stocks today IOVA Iovance Biotherapeutics $8.99 / +0.275 (+3.16%) 05/30/23 What You Missed On Wall Street On Tuesday 05/30/23 What You Missed On Wall Street This Morning 05/19/23 Biotech Alert: Searches spiking for these stocks today 18:00 Today Biotechnology--Pre-ASCO Reception 00:00 Today 2023 ASCO Annual Meeting 11/25/23 PDUFA Date for Lifileucel 06/06/23 Iovance Biotherapeutics, Inc. TECH RVNC TECH Bio-Techne $81.82 / +0.05 (+0.06%) 04/04/23 Early notable gainers among liquid option names on April 4th 12/28/22 Early notable gainers among liquid option names on December 28th RVNC Revance $30.77 / +0.22 (+0.72%) 01/09/23 Revance call volume above normal and directionally bullish

Wednesday
Conference/Events	Verastem participates in a conference call with Truist » 10:55 05/31/23 05/31 10:55 05/31/23 10:55 VSTM Verastem $1.01 / -0.03 (-2.90%) Biotech Analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events VSTM Verastem $1.01 / -0.03 (-2.90%) 05/31/23 Verastem announces 1-for-12 reverse stock split 05/25/23 Verastem's vutometinib shows 45% response rate in recurrent ovarian cancer 04/26/23 Interim analysis of Verastem's RAMP 201 trial to be presented at ASCO 01/24/23 Verastem reports interim data from Part A of the ongoing RAMP 201 Phase 2 study VSTM Verastem $1.01 / -0.03 (-2.90%) 05/10/23 H.C. Wainwright Verastem price target lowered to $2 from $3 at H.C. Wainwright 03/29/23 Mizuho Verastem initiated with a Neutral at Mizuho 11/07/22 H.C. Wainwright Verastem price target lowered to $3 from $5 at H.C. Wainwright 10/05/22 BTIG Verastem price target lowered to $5 from $8 at BTIG VSTM Verastem $1.01 / -0.03 (-2.90%) 05/09/23 Verastem reports Q1 EPS (9c), consensus (8c) 03/14/23 Verastem reports Q4 EPS (8c), consensus (10c) VSTM Verastem $1.01 / -0.03 (-2.90%) 03/14/23 Fly Intel: After-Hours Movers 18:00 Today Biotechnology--Pre-ASCO Reception 00:00 Today 2023 ASCO Annual Meeting 05/31/23 Verastem - VSTM
Hot Stocks	Verastem announces 1-for-12 reverse stock split » 09:20 05/31/23 05/31 09:20 05/31/23 09:20 VSTM Verastem $1.04 / +0.015 (+1.47%) Verastem announced that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 23:15:56 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events VSTM Verastem $1.04 / +0.015 (+1.47%) 05/25/23 Verastem's vutometinib shows 45% response rate in recurrent ovarian cancer 04/26/23 Interim analysis of Verastem's RAMP 201 trial to be presented at ASCO 01/24/23 Verastem reports interim data from Part A of the ongoing RAMP 201 Phase 2 study VSTM Verastem $1.04 / +0.015 (+1.47%) 05/10/23 H.C. Wainwright Verastem price target lowered to $2 from $3 at H.C. Wainwright 03/29/23 Mizuho Verastem initiated with a Neutral at Mizuho 11/07/22 H.C. Wainwright Verastem price target lowered to $3 from $5 at H.C. Wainwright 10/05/22 BTIG Verastem price target lowered to $5 from $8 at BTIG VSTM Verastem $1.04 / +0.015 (+1.47%) 05/09/23 Verastem reports Q1 EPS (9c), consensus (8c) 03/14/23 Verastem reports Q4 EPS (8c), consensus (10c) VSTM Verastem $1.04 / +0.015 (+1.47%) 03/14/23 Fly Intel: After-Hours Movers 18:00 Today Biotechnology--Pre-ASCO Reception 00:00 Today 2023 ASCO Annual Meeting 05/31/23 Verastem - VSTM
Conference/Events	Verastem participates in a conference call with Truist » 04:55 05/31/23 05/31 04:55 05/31/23 04:55 VSTM Verastem $1.04 / +0.015 (+1.47%) Biotech Analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 18:37:43 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events VSTM Verastem $1.04 / +0.015 (+1.47%) 05/25/23 Verastem's vutometinib shows 45% response rate in recurrent ovarian cancer 04/26/23 Interim analysis of Verastem's RAMP 201 trial to be presented at ASCO 01/24/23 Verastem reports interim data from Part A of the ongoing RAMP 201 Phase 2 study VSTM Verastem $1.04 / +0.015 (+1.47%) 05/10/23 H.C. Wainwright Verastem price target lowered to $2 from $3 at H.C. Wainwright 03/29/23 Mizuho Verastem initiated with a Neutral at Mizuho 11/07/22 H.C. Wainwright Verastem price target lowered to $3 from $5 at H.C. Wainwright 10/05/22 BTIG Verastem price target lowered to $5 from $8 at BTIG VSTM Verastem $1.04 / +0.015 (+1.47%) 05/09/23 Verastem reports Q1 EPS (9c), consensus (8c) 03/14/23 Verastem reports Q4 EPS (8c), consensus (10c) VSTM Verastem $1.04 / +0.015 (+1.47%) 03/14/23 Fly Intel: After-Hours Movers 18:00 Today Biotechnology--Pre-ASCO Reception 00:00 Today 2023 ASCO Annual Meeting 05/31/23 Verastem - VSTM

Tuesday
Conference/Events	Oppenheimer biotech analyst to hold a reception » 15:23 05/30/23 05/30 15:23 05/30/23 15:23 AGEN Agenus $1.44 / -0.005 (-0.35%) , CGEN Compugen $1.05 / -0.02 (-1.87%) , DAWN Day One Biopharmaceuticals $12.04 / -0.435 (-3.49%) , ERAS Erasca $2.61 / -0.215 (-7.62%) , IMRX Immuneering $6.93 / +0.44 (+6.78%) , KNTE Kinnate Biopharma $3.69 / -0.05 (-1.34%) , MRTX Mirati Therapeutics $37.36 / -1.15 (-2.99%) , RVMD Revolution Medicines $24.84 / -0.8 (-3.12%) , VIRX Viracta Therapeutics $1.33 / -0.11 (-7.64%) , ONCT Oncternal Therapeutics / + , BMEA Biomea Fusion $33.75 / +2.21 (+7.01%) , MRNA Moderna $128.65 / +2.38 (+1.88%) , REGN Regeneron $723.84 / -1.76 (-0.24%) , AZN AstraZeneca $71.39 / -1.12 (-1.54%) , GILD Gilead $76.36 / -0.72 (-0.93%) , VSTM Verastem $1.04 / +0.015 (+1.47%) , SWTX SpringsWorks Therapeutics $27.54 / -0.25 (-0.90%) Biotech Analysts… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 04:32:46 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options VSTM VIRX SWTX RVMD REGN ONCT MRTX MRNA KNTE IMRX GILD ERAS DAWN CGEN BMEA AZN AGEN VSTM Verastem $1.04 / +0.015 (+1.47%) 05/25/23 Verastem's vutometinib shows 45% response rate in recurrent ovarian cancer 04/26/23 Interim analysis of Verastem's RAMP 201 trial to be presented at ASCO 01/24/23 Verastem reports interim data from Part A of the ongoing RAMP 201 Phase 2 study VIRX Viracta Therapeutics $1.33 / -0.11 (-7.64%) 05/02/23 Viracta Therapeutics CMO Lisa Rojkjaer, M.D to depart 01/19/23 Viracta Therapeutics announces EC orphan drug designation for Nana-val 01/08/23 Viracta announces first clinical response in EBV+ solid tumor setting 11/30/22 Viracta reports Phase 1b/2 trial results for Nana-val in EBV+ tumors SWTX SpringsWorks Therapeutics $27.54 / -0.25 (-0.90%) 05/30/23 SpringsWorks Therapeutics says Phase 2 nirogacestat trial fully enrolled 04/17/23 MapKure, SpringWorks, BeiGene present data from Phase 1a/1b study of BGB-3245 02/27/23 SpringsWorks announces FDA acceptance, priority review of nirogacestat NDA 12/27/22 SpringsWorks Therapeutics completes submission of nirogacestat NDA to FDA RVMD Revolution Medicines $24.84 / -0.8 (-3.12%) 12/19/22 Revolution Medicines announces publication on design, synthesis of RMC-5552 12/07/22 Revolution to regain rights to RMC-4630 following Sanofi deal termination 12/07/22 Sanofi terminates SHP2 Inhibitor development pact with Revolution Medicines REGN Regeneron $723.84 / -1.76 (-0.24%) 05/25/23 Regeneron says updated Linvoseltamab data demonstrates durable responses 05/25/23 Regeneron reports 'positive' data from Fianlimab-Libtayo combo trial 05/21/23 Regeneron, Sanofi present Dupixent late-breaking Phase 3 COPD results 05/18/23 Sanofi 'pleased' with Supreme Court's ruling on Amgen's asserted patent claims ONCT Oncternal Therapeutics / + 04/03/23 Oncternal Therapeutics falls 41% to 46c per share after drug development halt 04/03/23 Oncternal Therapeutics trading resumes 04/03/23 Oncternal Therapeutics to resume trading at 4:30pm ET 04/03/23 Oncternal Therapeutics halts development of zilovertamab, ibrutinib combination MRTX Mirati Therapeutics $37.36 / -1.15 (-2.99%) 05/24/23 Mirati Therapeutics falls 10% after SAPPHIRE study did not meet primary endpoint 05/24/23 Mirati Therapeutics trading resumes 05/24/23 Mirati Therapeutics says SAPPHIRE study did not meet primary endpoint 05/24/23 Mirati Therapeutics trading halted, news pending MRNA Moderna $128.65 / +2.38 (+1.88%) 05/23/23 Moderna, BioNTech other Covid vaccine makers jump amid China Covid scare 05/19/23 Moderna reports interim data from Phase 1/2 trial of mRNA-3927 05/04/23 Moderna up 5% after Q1 results beat estimates 05/04/23 Moderna, Novocol Pharma enter long-term fill-finish agreement KNTE Kinnate Biopharma $3.69 / -0.05 (-1.34%) 04/17/23 Kinnate Biopharma adds two candidates to pipeline, provides cash runway guidance 04/17/23 Kinnate Biopharma announces 'positive' monotherapy dose escalation data 02/21/23 Kinnate Biopharma acquires ownership stake of Kinnjiu Biopharma for $24M 02/14/23 Kinnate Biopharma granted fast track designation for KIN-3248 from FDA IMRX Immuneering $6.93 / +0.44 (+6.78%) 04/18/23 Immuneering down 5% at $11.53 after pricing $30M stock offering 04/18/23 Immuneering announces initial Phase 1 PK, PD, safety data for IMM-1-104 03/28/23 Immuneering appoints Harold Brakewood as CBO 03/05/23 Immuneering presents preclinical data with lead program IMM-1-104 GILD Gilead $76.36 / -0.72 (-0.93%) 05/26/23 Gilead announces CHMP reccomendation for the use of Veklury 05/17/23 Gilead to present advances across its oncology pipeline at ASCO Annual Meeting 05/15/23 Arcus Biosciences jumps 2% amid expanded inflammation pact with Gilead 05/15/23 Expanded Gilead- Arcus pact may result in up to $1B in payments to Arcus ERAS Erasca $2.61 / -0.215 (-7.62%) 05/25/23 Erasca to present HERKULES-3 phase 1b data for ERAS-007 at ASCO 05/16/23 Erasca appoints Davd Chacko as CBO, Nik Chetwyn as COO 05/01/23 Erasca announces U.S. FDA granted FTD to ERAS-801 04/25/23 Erasca announces publication of clinical data on naporafenib DAWN Day One Biopharmaceuticals $12.04 / -0.435 (-3.49%) 01/08/23 Day One announces top line data from pivotal Phase 2 FIREFLY-1 trial CGEN Compugen $1.05 / -0.02 (-1.87%) 03/06/23 Compugen doses first patient in proof-of-concept study evaluating COM701 02/14/23 Compugen: Rilvegostomig expected to progress into Phase 3 this year 12/06/22 Compugen's COM701 shows durable anti-tumor activity in ovarian cancer 12/01/22 Compugen's COM701 shows preliminary anti-tumor activity in ovarian cancer BMEA Biomea Fusion $33.75 / +2.21 (+7.01%) 05/01/23 Biomea says FDA clearance of IND application to begin Phase I trial of BMF-500 04/19/23 Biomea Fusion to present late breaking data from Phase II trial, COVALENT-111 03/28/23 Biomea Fusion trading resumes 03/28/23 Biomea Fusion trading halted, volatility trading pause AZN AstraZeneca $71.39 / -1.12 (-1.54%) 05/30/23 BioLight announces joint cooperation agreement with AstraZeneca's Alexion 05/30/23 Catalyst Pharmaceuticals appoints Thompson to board of directors 05/30/23 Bolt Biotherapeutics and AstraZeneca Rare Disease partner in retinal disease R&D 05/26/23 AstraZeneca announces results from Imfinzi plus Lynparza trial AGEN Agenus $1.44 / -0.005 (-0.35%) 05/03/23 Agenus up 4% after FDA approves GSK's Arexvy RSV vaccine 04/26/23 Agenus to present Phase 1, Phase 2 trial data at ASCO meeting 04/17/23 Agenus receives Fast Track Designation from FDA for botensilimab, balstilimab 03/27/23 Agenus announces results from cohort in study of botensilimab with balstilimab AGEN CGEN DAWN ERAS IMRX KNTE MRTX RVMD VIRX ONCT BMEA MRNA REGN AZN GILD VSTM SWTX AGEN Agenus $1.44 / -0.005 (-0.35%) 05/25/23 EF Hutton Agenus assumed with a Buy at EF Hutton 05/09/23 H.C. Wainwright Agenus's progress continues with data presentations, says H.C. Wainwright 04/20/23 B. Riley B. Riley came away 'encouraged' on Agenus after AACR 02/28/23 H.C. Wainwright Agenus assumed with a Buy at H.C. Wainwright CGEN Compugen $1.05 / -0.02 (-1.87%) 02/08/23 Jefferies Compugen downgraded to Underperform from Hold at Jefferies 01/04/23 EF Hutton Compugen initiated with a Buy at EF Hutton 11/14/22 Oppenheimer Compugen price target lowered to $8 from $12 at Oppenheimer 08/23/22 Truist Compugen price target lowered to $4 from $14 at Truist DAWN Day One Biopharmaceuticals $12.04 / -0.435 (-3.49%) 05/01/23 Oppenheimer Day One language around NDA submission 'sounded ominous,' says Oppenheimer 05/01/23 H.C. Wainwright Day One pullback brings attractive entry point, says H.C. Wainwright 04/25/23 BofA Day One Biopharmaceuticals double downgraded at BofA on regulatory risks 04/25/23 BofA Day One Biopharmaceuticals downgraded to Underperform from Buy at BofA ERAS Erasca $2.61 / -0.215 (-7.62%) 03/29/23 Mizuho Erasca initiated with a Buy at Mizuho 02/24/23 Goldman Sachs Erasca initiated with a Buy at Goldman Sachs 02/03/23 Morgan Stanley Erasca upgraded to Overweight from Equal Weight at Morgan Stanley IMRX Immuneering $6.93 / +0.44 (+6.78%) 04/19/23 Mizuho Immuneering upgraded to Buy from Neutral at Mizuho 04/19/23 Morgan Stanley Immuneering upgraded to Equal Weight from Underweight at Morgan Stanley 04/18/23 Chardan Immuneering price target raised to $22 from $18 at Chardan 03/29/23 Mizuho Immuneering initiated with a Neutral at Mizuho KNTE Kinnate Biopharma $3.69 / -0.05 (-1.34%) 05/18/23 H.C. Wainwright Kinnate Biopharma price target lowered to $24 from $25 at H.C. Wainwright 04/20/23 H.C. Wainwright Kinnate Biopharma price target lowered to $25 from $33 at H.C. Wainwright 04/18/23 Stifel Kinnate Biopharma price target lowered to $5 from $8 at Stifel 04/18/23 Wedbush Kinnate Biopharma price target lowered to $14 from $25 at Wedbush MRTX Mirati Therapeutics $37.36 / -1.15 (-2.99%) 05/25/23 Oppenheimer Oppenheimer upgrades Mirati to Outperform with Krazati expectations reset 05/25/23 Oppenheimer Mirati Therapeutics upgraded to Outperform from Perform at Oppenheimer 05/25/23 BMO Capital Mirati Therapeutics price target lowered to $40 from $50 at BMO Capital 05/25/23 Barclays Mirati Therapeutics price target lowered to $75 from $90 at Barclays RVMD Revolution Medicines $24.84 / -0.8 (-3.12%) 05/09/23 JPMorgan Revolution Medicines price target lowered to $35 from $38 at JPMorgan 02/28/23 Needham Revolution Medicines price target raised to $38 from $32 at Needham 02/28/23 Oppenheimer Revolution Medicines price target raised to $35 from $30 at Oppenheimer 02/28/23 JPMorgan Revolution Medicines upgraded to Overweight from Neutral at JPMorgan VIRX Viracta Therapeutics $1.33 / -0.11 (-7.64%) 05/10/23 H.C. Wainwright Viracta Therapeutics price target lowered to $33 from $35 at H.C. Wainwright ONCT Oncternal Therapeutics / + 04/06/23 Cantor Fitzgerald Oncternal downgraded to Neutral from Overweight at Cantor Fitzgerald 04/04/23 Maxim Oncternal Therapeutics downgraded to Hold from Buy at Maxim 04/04/23 Cantor Fitzgerald Oncternal Therapeutics price target lowered to $1.30 from $4.00 at Cantor Fitzgerald 04/04/23 H.C. Wainwright Oncternal Therapeutics downgraded to Neutral from Buy at H.C. Wainwright BMEA Biomea Fusion $33.75 / +2.21 (+7.01%) 05/25/23 EF Hutton Biomea Fusion assumed with a Buy at EF Hutton 05/18/23 Citi Biomea Fusion price target lowered to $53 from $55 at Citi 05/12/23 Barclays Biomea Fusion initiated with an Overweight at Barclays 04/19/23 H.C. Wainwright Biomea Fusion price target lowered to $37 from $44 at H.C. Wainwright MRNA Moderna $128.65 / +2.38 (+1.88%) 05/05/23 Morgan Stanley Moderna price target lowered to $153 from $185 at Morgan Stanley 04/25/23 Guggenheim Moderna initiated with a Neutral at Guggenheim 04/13/23 Baird Carisma Therapeutics initiated with an Outperform at Baird 04/12/23 BofA BofA says 'left with more questions than answers' after Moderna Vaccines Day REGN Regeneron $723.84 / -1.76 (-0.24%) 05/19/23 Piper Sandler Regeneron Q1 Eylea miss 'not about share, says Piper Sandler 05/08/23 Guggenheim Regeneron price target lowered to $935 from $960 at Guggenheim 05/05/23 Morgan Stanley Regeneron price target raised to $927 from $880 at Morgan Stanley 05/05/23 SVB Securities Regeneron price target lowered to $895 from $976 at SVB Securities AZN AstraZeneca $71.39 / -1.12 (-1.54%) 05/26/23 Argus AstraZeneca price target lowered to $80 from $85 at Argus 05/09/23 Berenberg AstraZeneca price target raised to 135 GBp from 124 GBp at Berenberg 04/28/23 JPMorgan AstraZeneca price target raised to 14,000 GBp from 13,500 GBp at JPMorgan 04/13/23 Argus AstraZeneca price target raised to $85 from $75 at Argus GILD Gilead $76.36 / -0.72 (-0.93%) 05/16/23 BMO Capital Gilead upgraded to Outperform from Market Perform at BMO Capital 04/28/23 Piper Sandler Gilead assumed with an Overweight at Piper Sandler 04/12/23 Morgan Stanley Gilead price target raised to $85 from $81 at Morgan Stanley 04/05/23 Guggenheim InflaRx upgraded to Buy at Guggenheim after Gohibic gets COVID EUA VSTM Verastem $1.04 / +0.015 (+1.47%) 05/10/23 H.C. Wainwright Verastem price target lowered to $2 from $3 at H.C. Wainwright 03/29/23 Mizuho Verastem initiated with a Neutral at Mizuho 11/07/22 H.C. Wainwright Verastem price target lowered to $3 from $5 at H.C. Wainwright 10/05/22 BTIG Verastem price target lowered to $5 from $8 at BTIG SWTX SpringsWorks Therapeutics $27.54 / -0.25 (-0.90%) 04/28/23 Barclays SpringsWorks Therapeutics price target lowered to $41 from $55 at Barclays 03/07/23 H.C. Wainwright SpringsWorks Therapeutics price target raised to $105 from $99 at H.C. Wainwright 01/02/23 Barclays Barclays views GSK acquisition interest as positive for oncology stocks 12/01/22 BofA SpringsWorks Therapeutics initiated with a Buy, $45 price target at BofA VSTM VIRX SWTX RVMD REGN ONCT MRTX MRNA KNTE GILD ERAS DAWN CGEN BMEA AZN AGEN VSTM Verastem $1.04 / +0.015 (+1.47%) 05/09/23 Verastem reports Q1 EPS (9c), consensus (8c) 03/14/23 Verastem reports Q4 EPS (8c), consensus (10c) VIRX Viracta Therapeutics $1.33 / -0.11 (-7.64%) 05/08/23 Viracta Therapeutics reports Q1 EPS (32c), consensus (31c) 03/13/23 Viracta Therapeutics reports Q4 EPS (27c), consensus (38c) SWTX SpringsWorks Therapeutics $27.54 / -0.25 (-0.90%) 05/03/23 SpringsWorks Therapeutics reports Q1 EPS ($1.18), consensus ($1.25) 02/28/23 SpringsWorks Therapeutics reports Q4 EPS ($1.19), consensus ($1.22) RVMD Revolution Medicines $24.84 / -0.8 (-3.12%) 05/08/23 Revolution Medicines reports Q1 EPS (72c), consensus (81c) 02/27/23 Revolution Medicines sees FY23 net loss $335M-$365M 02/27/23 Revolution Medicines reports Q4 EPS (63c), consensus (82c) REGN Regeneron $723.84 / -1.76 (-0.24%) 05/04/23 Regeneron reports Q1 adjusted EPS $10.09, consensus $9.56 02/03/23 Regeneron reports Q4 adjusted EPS $12.56, consensus $10.03 02/02/23 Notable companies reporting before tomorrow's open ONCT Oncternal Therapeutics / + 05/04/23 Oncternal Therapeutics reports Q1 EPS (20c), consensus (20c) MRTX Mirati Therapeutics $37.36 / -1.15 (-2.99%) 05/09/23 Mirati Therapeutics reports Q1 EPS ($3.18), consensus ($3.55) 02/28/23 Mirati Therapeutics reports Q4 EPS ($3.51), consensus ($3.55) MRNA Moderna $128.65 / +2.38 (+1.88%) 05/04/23 Moderna sees Q2 sales $200M-$300M, consensus $982.37M 02/23/23 Moderna reports Q4 EPS $3.61, consensus $4.67 02/22/23 Notable companies reporting before tomorrow's open KNTE Kinnate Biopharma $3.69 / -0.05 (-1.34%) 05/11/23 Kinnate Biopharma reports Q1 EPS (73c), consensus (73c) GILD Gilead $76.36 / -0.72 (-0.93%) 05/15/23 Gilead: Arcus deal may reduce Gilead's FY23 GAAP and non-GAAP EPS by 2c 04/27/23 Gilead backs FY23 adjusted EPS view $6.60-$7.00, consensus $6.84 04/27/23 Gilead reports Q1 Biktarvy sales up 24% y/y 04/27/23 Gilead Sciences reports Q1 adjusted EPS $1.37, consensus $1.54 ERAS Erasca $2.61 / -0.215 (-7.62%) 05/15/23 Erasca reports Q1 EPS (22c), consensus (31c) 03/23/23 Erasca reports Q4 EPS ($1.06) vs. (26c) last year DAWN Day One Biopharmaceuticals $12.04 / -0.435 (-3.49%) 05/01/23 Day One Biopharmaceuticals reports Q1 EPS (59c), consensus (59c) CGEN Compugen $1.05 / -0.02 (-1.87%) 05/15/23 Compugen reports Q1 EPS (11c), consensus (12c) 03/10/23 Compugen considers exposure to SVB Financial as immaterial 02/27/23 Compugen reports Q4 EPS (4c), consensus (14c) BMEA Biomea Fusion $33.75 / +2.21 (+7.01%) 05/02/23 Biomea Fusion reports Q1 EPS (98c), consensus (81c) 03/28/23 Biomea Fusion reports Q4 EPS (21c), consensus (81c) AZN AstraZeneca $71.39 / -1.12 (-1.54%) 04/27/23 AstraZeneca sees FY23 core EPS up high single to low double-digit percentage 04/27/23 AstraZeneca reports Q1 core EPS $1.92, consensus $1.07 02/09/23 AstraZeneca sees FY23 core EPS up high single to low double-digit percentage 02/09/23 AstraZeneca reports Q4 core EPS $1.38, consensus $1.35 AGEN Agenus $1.44 / -0.005 (-0.35%) 05/09/23 Agenus reports Q1 EPS (22c), consensus (21c) 03/14/23 Agenus reports Q4 EPS (24c), consensus (22c) 18 Apr 30 Mar 03 Mar 09 Dec 20 Jul 15 Jun REGN MRTX MRNA AZN REGN Regeneron $723.84 / -1.76 (-0.24%) 05/17/23 Regeneron CEO backs regulators attempt to block Amgen deal, FT reports MRTX Mirati Therapeutics $37.36 / -1.15 (-2.99%) 05/09/23 Boxer's Davis pitches Mirati Therapeutics as long idea at Sohn MRNA Moderna $128.65 / +2.38 (+1.88%) 05/26/23 Health authorities to target next COVID shot to new strain, WSJ says 05/23/23 China's new Covid surge could result in 65M infections a week, Bloomberg says 03/23/23 Moderna CEO defends $130 price of Covid-19 vaccine, Reuters reports 03/21/23 FDA moving towards authorizing second omicron booster, WSJ reports AZN AstraZeneca $71.39 / -1.12 (-1.54%) 05/19/23 Astra China head says company seeks to 'love the Communist Party,' Reuters says 05/04/23 AstraZeneca chair says increasing CEO's pay wards of rivals, FT reports 04/06/23 GSK unit ordered to pay AstraZeneca royalties on Zejula sales, Reuters says VSTM SWTX RVMD REGN ONCT MRTX MRNA KNTE GILD ERAS DAWN BMEA AZN AGEN VSTM Verastem $1.04 / +0.015 (+1.47%) 03/14/23 Fly Intel: After-Hours Movers SWTX SpringsWorks Therapeutics $27.54 / -0.25 (-0.90%) 04/22/23 Short Report: Bears pare exposure in crypto stocks as bitcoin slumps RVMD Revolution Medicines $24.84 / -0.8 (-3.12%) 02/28/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations REGN Regeneron $723.84 / -1.76 (-0.24%) 03/28/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/27/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/24/23 What You Missed On Wall Street On Friday 03/24/23 What You Missed On Wall Street This Morning ONCT Oncternal Therapeutics / + 04/06/23 Biotech Alert: Searches spiking for these stocks today 04/04/23 Fly Intel: Pre-market Movers 04/03/23 Fly Intel: After-Hours Movers 12/07/22 Biotech Alert: Searches spiking for these stocks today MRTX Mirati Therapeutics $37.36 / -1.15 (-2.99%) 05/25/23 Fly Intel: Pre-market Movers 02/19/23 Short Report: Bearish bets in crypto arena renewed as coins and stocks rebound 12/31/22 Short Report: Bearish views reach record high on Silvergate, Mirati Therapeutics 12/16/22 Sell these stocks now, proven algorithm says MRNA Moderna $128.65 / +2.38 (+1.88%) 04/26/23 What You Missed On Wall Street On Wednesday 04/26/23 What You Missed On Wall Street This Morning 04/14/23 Biotech Alert: Searches spiking for these stocks today 04/13/23 Biotech Alert: Searches spiking for these stocks today KNTE Kinnate Biopharma $3.69 / -0.05 (-1.34%) 05/15/23 Fly Insider: Kinnate Biopharma, Arrowhead among week's notable insider trades GILD Gilead $76.36 / -0.72 (-0.93%) 05/16/23 What You Missed On Wall Street On Tuesday 05/16/23 What You Missed On Wall Street This Morning 05/16/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/28/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ERAS Erasca $2.61 / -0.215 (-7.62%) 03/23/23 Fly Intel: After-Hours Movers 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/09/22 What You Missed On Wall Street On Friday 12/09/22 What You Missed On Wall Street This Morning DAWN Day One Biopharmaceuticals $12.04 / -0.435 (-3.49%) 04/28/23 Buy/Sell: Wall Street's top 10 stock calls this week 04/25/23 What You Missed On Wall Street On Tuesday 04/25/23 What You Missed On Wall Street This Morning 04/25/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations BMEA Biomea Fusion $33.75 / +2.21 (+7.01%) 04/10/23 Fly Insider: Planet Labs, C3.ai among week's notable insider trades 03/28/23 What You Missed On Wall Street On Tuesday 03/28/23 What You Missed On Wall Street This Morning AZN AstraZeneca $71.39 / -1.12 (-1.54%) 04/11/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/05/23 What You Missed On Wall Street On Wednesday 04/05/23 What You Missed On Wall Street This Morning 02/09/23 What You Missed On Wall Street This Morning AGEN Agenus $1.44 / -0.005 (-0.35%) 04/17/23 What You Missed On Wall Street On Monday 04/17/23 What You Missed On Wall Street This Morning 01/23/23 What You Missed On Wall Street On Monday 01/23/23 What You Missed On Wall Street This Morning 18:00 Today Biotechnology--Pre-ASCO Reception 06/09/23 Biotechnology 06/12/23 Biotech/Biopharma 05/30/23 4th Annual Oncology Innovation Summit: Insights for ASCO & EHA 00:00 Today 2023 ASCO Annual Meeting 09/19/23 Institutional Investor Conference 2023 05/31/23 Verastem - VSTM 06/27/23 PDUFA Date for Eylea 08/20/23 PDUFA Date for Pozelimab 08/27/23 PDUFA Date for Nirogacestat 12/22/23 PDUFA Date for Eplontersen 06/08/23 Revolution Medicines, Inc. 06/08/23 Viracta Therapeutics Inc 06/09/23 Regeneron Pharmaceuticals 06/09/23 Kinnate Biopharma Inc. 06/12/23 Agenus Inc. 06/13/23 Compugen 06/14/23 Compugen 06/14/23 Immuneering Corp. 06/14/23 BioMea Fusion, Inc. 06/15/23 Compugen 06/22/23 Day One Biopharmaceuticals, Inc 06/22/23 Erasca, Inc. 06/28/23 Oncternal Therapeutics Inc REGN MRNA GILD BMEA AZN REGN Regeneron $723.84 / -1.76 (-0.24%) 03/23/23 Early notable gainers among liquid option names on March 23rd MRNA Moderna $128.65 / +2.38 (+1.88%) 05/24/23 Unusually active option classes on open May 24th 05/23/23 Moderna call volume above normal and directionally bullish 05/23/23 Early notable gainers among liquid option names on May 23rd 04/17/23 Unusually active option classes on open April 17th GILD Gilead $76.36 / -0.72 (-0.93%) 05/25/23 Gilead call volume above normal and directionally bullish 05/03/23 Gilead call volume above normal and directionally bullish 04/27/23 Gilead options imply 3.8% move in share price post-earnings 02/03/23 Early notable gainers among liquid option names on February 3rd BMEA Biomea Fusion $33.75 / +2.21 (+7.01%) 03/28/23 Biomea Fusion options imply 11.3% move in share price post-earnings AZN AstraZeneca $71.39 / -1.12 (-1.54%) 05/26/23 Unusually active option classes on open May 26th 05/18/23 Unusually active option classes on open May 18th 05/09/23 AstraZeneca put volume heavy and directionally bearish 04/27/23 Unusually active option classes on open April 27th

Over a week ago
Hot Stocks	Verastem's vutometinib shows 45% response rate in recurrent ovarian cancer » 17:10 05/25/23 05/25 17:10 05/25/23 17:10 VSTM Verastem / + Verastem announced… Verastem announced updated data from Part A of the ongoing registration-directed RAMP 201 trial evaluating the safety and efficacy of avutometinib alone and in combination with defactinib among patients with recurrent low-grade serous ovarian cancer - LGSOC -. In the RAMP 201 study, treatment with the combination of avutometinib and defactinib resulted in an objective response rate of 45% - 13/29 - and tumor shrinkage in 86% of evaluable patients. Safety and tolerability continued to be favorable and consistent with previously reported data. These data build on the Breakthrough Therapy Designation granted by the FDA for the combination in recurrent LGSOC. The safety profile was consistent with previously reported safety data. The discontinuation rate, due to greater than or equal to 1 adverse event, was 12% in the trial overall to date. The company plans to include data to support filing for accelerated approval. The company is finalizing the design of a randomized confirmatory trial with the FDA, which is planned to begin in the second half of 2023. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events VSTM Verastem / + 04/26/23 Interim analysis of Verastem's RAMP 201 trial to be presented at ASCO 01/24/23 Verastem reports interim data from Part A of the ongoing RAMP 201 Phase 2 study VSTM Verastem / + 05/10/23 H.C. Wainwright Verastem price target lowered to $2 from $3 at H.C. Wainwright 03/29/23 Mizuho Verastem initiated with a Neutral at Mizuho 11/07/22 H.C. Wainwright Verastem price target lowered to $3 from $5 at H.C. Wainwright 10/05/22 BTIG Verastem price target lowered to $5 from $8 at BTIG VSTM Verastem / + 05/09/23 Verastem reports Q1 EPS (9c), consensus (8c) 03/14/23 Verastem reports Q4 EPS (8c), consensus (10c) VSTM Verastem / + 03/14/23 Fly Intel: After-Hours Movers 18:00 Today Biotechnology--Pre-ASCO Reception 00:00 Today 2023 ASCO Annual Meeting 05/31/23 Verastem - VSTM
Conference/Events	Verastem participates in a conference call with Truist » 15:22 05/24/23 05/24 15:22 05/24/23 15:22 VSTM Verastem / + Biotech Analyst… Biotech Analyst Devarakonda, along with CEO Stuglik discuss the upcoming ASCO 2023 Annual Meeting on a conference call to be held on May 31 at 11 am. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events VSTM Verastem / + 04/26/23 Interim analysis of Verastem's RAMP 201 trial to be presented at ASCO 01/24/23 Verastem reports interim data from Part A of the ongoing RAMP 201 Phase 2 study VSTM Verastem / + 05/10/23 H.C. Wainwright Verastem price target lowered to $2 from $3 at H.C. Wainwright 03/29/23 Mizuho Verastem initiated with a Neutral at Mizuho 11/07/22 H.C. Wainwright Verastem price target lowered to $3 from $5 at H.C. Wainwright 10/05/22 BTIG Verastem price target lowered to $5 from $8 at BTIG VSTM Verastem / + 05/09/23 Verastem reports Q1 EPS (9c), consensus (8c) 03/14/23 Verastem reports Q4 EPS (8c), consensus (10c) VSTM Verastem / + 03/14/23 Fly Intel: After-Hours Movers 05/24/23 Biotechnology 18:00 Today Biotechnology--Pre-ASCO Reception 00:00 Today 2023 ASCO Annual Meeting 05/31/23 Verastem - VSTM
Conference/Events	Mizuho biotech analyst to hold an analyst/industry conference call » 09:50 05/24/23 05/24 09:50 05/24/23 09:50 ERAS Erasca $2.96 / -0.03 (-1.00%) , IMRX Immuneering $6.95 / + (+0.00%) , VSTM Verastem / + , MRK Merck $112.88 / -0.42 (-0.37%) , INCY Incyte $64.67 / -0.435 (-0.67%) , EFTR eFfector Therapeutics / + , LPTX Leap Therapeutics / + , RCUS Arcus Biosciences $17.94 / -0.14 (-0.77%) , CRVS Corvus Pharmaceuticals $3.00 / -0.09 (-2.91%) Biotechnology Analyst… Biotechnology Analyst Goldstein, along with Drs. Velcheti and Oberstein discuss targeted therapies in lung and GI cancer, (ERAS, IMRX, VSTM, MRK, INCY, EFTR, LPTX, RCUS, CRVS) as well as emerging trends and themes to be covered at the upcoming ASCO 2023 Annual Meeting on an Analyst/Industry conference call to be held on May 24 at 10 am. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options VSTM RCUS MRK LPTX INCY IMRX ERAS EFTR CRVS VSTM Verastem / + 04/26/23 Interim analysis of Verastem's RAMP 201 trial to be presented at ASCO 01/24/23 Verastem reports interim data from Part A of the ongoing RAMP 201 Phase 2 study RCUS Arcus Biosciences $17.94 / -0.14 (-0.77%) 05/15/23 Arcus Biosciences jumps 2% amid expanded inflammation pact with Gilead 05/15/23 Expanded Gilead- Arcus pact may result in up to $1B in payments to Arcus 05/15/23 Arcus to receive upfront payment of $35M from Gilead in expanded research pact 12/20/22 Arcus Biosciences falls -30.2% MRK Merck $112.88 / -0.42 (-0.37%) 05/17/23 Immutep announces results from Phse II TACTI-002 trial 05/16/23 Prometheus, Seagen slip after FTC sues to block Horizon acquisition 05/16/23 OncoSec reports Type C meeting with FDA for melanoma treatment 05/15/23 Canadian Solar subsidiary signs aggregation deal for 100MW in Texas LPTX Leap Therapeutics / + 04/12/23 Leap Therapeutics completes enrollment in Part A of DeFianCe study of DKN-01 03/16/23 Leap Therapeutics provides update on BeiGene option agreement for DKN-01 01/17/23 Leap Therapeutics acquires Flame Biosciences INCY Incyte $64.67 / -0.435 (-0.67%) 05/02/23 Incyte tightens Jakafi net product revenues view $2.55B - $2.63B 05/01/23 Incyte says SCRATCH-AD trial meets primary endpoint 04/20/23 Incyte reports EC approval of Opzelura for non-segmental vitiligo repigmentation 04/16/23 MorphoSys, Incyte announce five-year follow-up data from Phase 2 L-MIND study IMRX Immuneering $6.95 / + (+0.00%) 04/18/23 Immuneering down 5% at $11.53 after pricing $30M stock offering 04/18/23 Immuneering announces initial Phase 1 PK, PD, safety data for IMM-1-104 03/28/23 Immuneering appoints Harold Brakewood as CBO 03/05/23 Immuneering presents preclinical data with lead program IMM-1-104 ERAS Erasca $2.96 / -0.03 (-1.00%) 05/16/23 Erasca appoints Davd Chacko as CBO, Nik Chetwyn as COO 05/01/23 Erasca announces U.S. FDA granted FTD to ERAS-801 04/25/23 Erasca announces publication of clinical data on naporafenib 04/18/23 Erasca presents Phase 1b dose escalation data from FLAGSHIP-1 for ERAS-601 EFTR eFfector Therapeutics / + 04/11/23 eFfector Therapeutics to collaborate with Standford Medicine 02/21/23 eFfector announces top-line results from Phase 1b trial of zotatifin 01/05/23 eFfector Therapeutics provides clinical data update for Zotatifin CRVS Corvus Pharmaceuticals $3.00 / -0.09 (-2.91%) 05/17/23 Corvus Pharmaceuticals to present new CPI-818 data at ICML meeting 04/17/23 Corvus Pharmaceuticals presents new data for CPI-818 04/03/23 Corvus Pharmaceuticals announces interim data on CPI-818 02/21/23 Corvus Pharmaceuticals announces new data on CPI-818 ERAS IMRX VSTM MRK INCY EFTR LPTX RCUS CRVS ERAS Erasca $2.96 / -0.03 (-1.00%) 03/29/23 Mizuho Erasca initiated with a Buy at Mizuho 02/24/23 Goldman Sachs Erasca initiated with a Buy at Goldman Sachs 02/03/23 Morgan Stanley Erasca upgraded to Overweight from Equal Weight at Morgan Stanley IMRX Immuneering $6.95 / + (+0.00%) 04/19/23 Mizuho Immuneering upgraded to Buy from Neutral at Mizuho 04/19/23 Morgan Stanley Immuneering upgraded to Equal Weight from Underweight at Morgan Stanley 04/18/23 Chardan Immuneering price target raised to $22 from $18 at Chardan 03/29/23 Mizuho Immuneering initiated with a Neutral at Mizuho VSTM Verastem / + 05/10/23 H.C. Wainwright Verastem price target lowered to $2 from $3 at H.C. Wainwright 03/29/23 Mizuho Verastem initiated with a Neutral at Mizuho 11/07/22 H.C. Wainwright Verastem price target lowered to $3 from $5 at H.C. Wainwright 10/05/22 BTIG Verastem price target lowered to $5 from $8 at BTIG MRK Merck $112.88 / -0.42 (-0.37%) 05/10/23 Jefferies Prometheus downgraded to Hold from Buy at Jefferies 05/01/23 Barclays Merck price target raised to $130 from $128 at Barclays 04/18/23 Wells Fargo Prometheus downgraded to Equal Weight from Overweight at Wells Fargo 04/18/23 RBC Capital Prometheus downgraded to Sector Perform from Outperform at RBC Capital INCY Incyte $64.67 / -0.435 (-0.67%) 05/04/23 JMP Securities Incyte price target lowered to $93 from $113 at JMP Securities 05/04/23 BofA Incyte downgraded to Neutral at BofA on long-term value uncertainty 05/04/23 BofA Incyte downgraded to Neutral from Buy at BofA 05/03/23 BMO Capital Incyte price target lowered to $70 from $75 at BMO Capital EFTR eFfector Therapeutics / + LPTX Leap Therapeutics / + 03/17/23 Piper Sandler Leap Therapeutics news 'disappointing at first glance,' says Piper Sandler 03/17/23 Mizuho Leap Therapeutics price target lowered to $2 from $3 at Mizuho 01/27/23 Mizuho Leap Therapeutics price target lowered to $3 from $6 at Mizuho 01/17/23 Piper Sandler Leap Therapeutics price target lowered to $3 from $4 at Piper Sandler RCUS Arcus Biosciences $17.94 / -0.14 (-0.77%) 03/09/23 Citi Arcus Biosciences price target lowered to $40 from $42 at Citi 12/21/22 Citi Arcus Biosciences selloff a buying opportunity, says Citi 12/21/22 Barclays Arcus Biosciences price target lowered to $36 from $60 at Barclays 12/20/22 Citi Arcus Biosciences price target raised to $42 from $37 at Citi CRVS Corvus Pharmaceuticals $3.00 / -0.09 (-2.91%) 05/09/23 Cantor Fitzgerald Corvus Pharmaceuticals price target raised to $4 from $2 at Cantor Fitzgerald 10/07/22 Ladenburg Corvus Pharmaceuticals initiated with a Buy at Ladenburg 08/09/22 Cantor Fitzgerald Corvus Pharmaceuticals price target lowered to $4 from $8 at Cantor Fitzgerald VSTM RCUS MRK LPTX INCY ERAS EFTR CRVS VSTM Verastem / + 05/09/23 Verastem reports Q1 EPS (9c), consensus (8c) 03/14/23 Verastem reports Q4 EPS (8c), consensus (10c) RCUS Arcus Biosciences $17.94 / -0.14 (-0.77%) 05/09/23 Arcus Biosciences reports Q1 EPS ($1.09), consensus ($1.16) 02/28/23 Arcus Biosciences reports Q4 EPS (93c), consensus ($1.07) MRK Merck $112.88 / -0.42 (-0.37%) 04/27/23 Merck narrows FY23 revenue view to $57.7B-$58.9B from $57.2B-$58.7B 04/27/23 Merck reports Q1 adjusted EPS $1.40, consensus $1.32 04/26/23 Notable companies reporting before tomorrow's open LPTX Leap Therapeutics / + 05/15/23 Leap Therapeutics reports Q1 EPS (32c), consensus (10c) 03/24/23 Leap Therapeutics reports Q4 EPS (11c), consensus (11c) INCY Incyte $64.67 / -0.435 (-0.67%) 05/02/23 Incyte reports Q1 EPS 37c, consensus 75c 02/07/23 Incyte reports Q4 EPS 62c, consensus 58c 02/06/23 Notable companies reporting before tomorrow's open ERAS Erasca $2.96 / -0.03 (-1.00%) 05/15/23 Erasca reports Q1 EPS (22c), consensus (31c) 03/23/23 Erasca reports Q4 EPS ($1.06) vs. (26c) last year EFTR eFfector Therapeutics / + 05/09/23 eFfector Therapeutics reports Q1 EPS (24c), consensus (14c) 03/08/23 eFfector Therapeutics reports Q4 EPS (22c), consensus (24c) CRVS Corvus Pharmaceuticals $3.00 / -0.09 (-2.91%) 05/08/23 Corvus Pharmaceuticals reports Q1 EPS (17c), consensus (16c) 18 Apr 09 Dec MRK MRK Merck $112.88 / -0.42 (-0.37%) 02/27/23 Pfizer in talks to buy Seagen in deal that may be valued at over $30B, WSJ says 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 01/11/23 Merck, Pfizer rebuff China's efforts to cut Covid drug prices, Bloomberg says 12/30/22 Merck's Covid treatment gets conditional approval in China, Reuters reports VSTM RCUS MRK LPTX INCY ERAS VSTM Verastem / + 03/14/23 Fly Intel: After-Hours Movers RCUS Arcus Biosciences $17.94 / -0.14 (-0.77%) 12/20/22 What You Missed On Wall Street On Tuesday 12/20/22 What You Missed On Wall Street This Morning 12/19/22 Fly Intel: After-Hours Movers 11/30/22 Biotech Alert: Searches spiking for these stocks today MRK Merck $112.88 / -0.42 (-0.37%) 05/16/23 What You Missed On Wall Street On Tuesday 04/27/23 Fly Intel: Pre-market Movers 04/19/23 Biotech Alert: Searches spiking for these stocks today 04/17/23 What You Missed On Wall Street On Monday LPTX Leap Therapeutics / + 05/19/23 Biotech Alert: Searches spiking for these stocks today 03/24/23 What You Missed On Wall Street On Friday 03/24/23 What You Missed On Wall Street This Morning INCY Incyte $64.67 / -0.435 (-0.67%) 05/05/23 Biotech Alert: Searches spiking for these stocks today 05/04/23 Biotech Alert: Searches spiking for these stocks today 05/02/23 Fly Intel: Pre-market Movers 04/10/23 What You Missed On Wall Street On Monday ERAS Erasca $2.96 / -0.03 (-1.00%) 03/23/23 Fly Intel: After-Hours Movers 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/09/22 What You Missed On Wall Street On Friday 12/09/22 What You Missed On Wall Street This Morning 05/24/23 Biotechnology 18:00 Today Biotechnology--Pre-ASCO Reception 06/09/23 Biotechnology 06/12/23 Biotech/Biopharma 00:00 Today 2023 ASCO Annual Meeting 05/31/23 Verastem - VSTM 08/01/23 Merck - MRK 05/24/23 Immuneering 06/14/23 Incyte Corporation 06/14/23 Immuneering Corp. 06/15/23 Arcus Biosciences, Inc. 06/15/23 Corvus Pharmaceuticals, Inc. 06/16/23 Leap Therapeutics, Inc. 06/22/23 Erasca, Inc. 06/22/23 eFFECTOR Therapeutics Inc MRK MRK Merck $112.88 / -0.42 (-0.37%) 04/25/23 Merck call volume above normal and directionally bullish 04/17/23 Unusually active option classes on open April 17th 03/10/23 Early notable gainers among liquid option names on March 10th 01/10/23 Largest borrow rate increases among liquid names
Conference/Events	Mizuho biotech analyst to hold an analyst/industry conference call » 04:55 05/24/23 05/24 04:55 05/24/23 04:55 ERAS Erasca $3.00 / +0.075 (+2.57%) , IMRX Immuneering $6.95 / -1.23 (-15.04%) , VSTM Verastem / + , MRK Merck $113.28 / -1.175 (-1.03%) , INCY Incyte $65.11 / +0.715 (+1.11%) , EFTR eFfector Therapeutics / + , LPTX Leap Therapeutics / + , RCUS Arcus Biosciences $18.06 / -0.08 (-0.44%) , CRVS Corvus Pharmaceuticals $3.09 / -0.28 (-8.31%) Biotechnology Analyst… Biotechnology Analyst Goldstein, along with Drs. Velcheti and Oberstein discuss targeted therapies in lung and GI cancer, (ERAS, IMRX, VSTM, MRK, INCY, EFTR, LPTX, RCUS, CRVS) as well as emerging trends and themes to be covered at the upcoming ASCO 2023 Annual Meeting on an Analyst/Industry conference call to be held on May 24 at 10 am. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options VSTM RCUS MRK LPTX INCY IMRX ERAS EFTR CRVS VSTM Verastem / + 04/26/23 Interim analysis of Verastem's RAMP 201 trial to be presented at ASCO 01/24/23 Verastem reports interim data from Part A of the ongoing RAMP 201 Phase 2 study RCUS Arcus Biosciences $18.06 / -0.08 (-0.44%) 05/15/23 Arcus Biosciences jumps 2% amid expanded inflammation pact with Gilead 05/15/23 Expanded Gilead- Arcus pact may result in up to $1B in payments to Arcus 05/15/23 Arcus to receive upfront payment of $35M from Gilead in expanded research pact 12/20/22 Arcus Biosciences falls -30.2% MRK Merck $113.28 / -1.175 (-1.03%) 05/17/23 Immutep announces results from Phse II TACTI-002 trial 05/16/23 Prometheus, Seagen slip after FTC sues to block Horizon acquisition 05/16/23 OncoSec reports Type C meeting with FDA for melanoma treatment 05/15/23 Canadian Solar subsidiary signs aggregation deal for 100MW in Texas LPTX Leap Therapeutics / + 04/12/23 Leap Therapeutics completes enrollment in Part A of DeFianCe study of DKN-01 03/16/23 Leap Therapeutics provides update on BeiGene option agreement for DKN-01 01/17/23 Leap Therapeutics acquires Flame Biosciences INCY Incyte $65.11 / +0.715 (+1.11%) 05/02/23 Incyte tightens Jakafi net product revenues view $2.55B - $2.63B 05/01/23 Incyte says SCRATCH-AD trial meets primary endpoint 04/20/23 Incyte reports EC approval of Opzelura for non-segmental vitiligo repigmentation 04/16/23 MorphoSys, Incyte announce five-year follow-up data from Phase 2 L-MIND study IMRX Immuneering $6.95 / -1.23 (-15.04%) 04/18/23 Immuneering down 5% at $11.53 after pricing $30M stock offering 04/18/23 Immuneering announces initial Phase 1 PK, PD, safety data for IMM-1-104 03/28/23 Immuneering appoints Harold Brakewood as CBO 03/05/23 Immuneering presents preclinical data with lead program IMM-1-104 ERAS Erasca $3.00 / +0.075 (+2.57%) 05/16/23 Erasca appoints Davd Chacko as CBO, Nik Chetwyn as COO 05/01/23 Erasca announces U.S. FDA granted FTD to ERAS-801 04/25/23 Erasca announces publication of clinical data on naporafenib 04/18/23 Erasca presents Phase 1b dose escalation data from FLAGSHIP-1 for ERAS-601 EFTR eFfector Therapeutics / + 04/11/23 eFfector Therapeutics to collaborate with Standford Medicine 02/21/23 eFfector announces top-line results from Phase 1b trial of zotatifin 01/05/23 eFfector Therapeutics provides clinical data update for Zotatifin CRVS Corvus Pharmaceuticals $3.09 / -0.28 (-8.31%) 05/17/23 Corvus Pharmaceuticals to present new CPI-818 data at ICML meeting 04/17/23 Corvus Pharmaceuticals presents new data for CPI-818 04/03/23 Corvus Pharmaceuticals announces interim data on CPI-818 02/21/23 Corvus Pharmaceuticals announces new data on CPI-818 ERAS IMRX VSTM MRK INCY EFTR LPTX RCUS CRVS ERAS Erasca $3.00 / +0.075 (+2.57%) 03/29/23 Mizuho Erasca initiated with a Buy at Mizuho 02/24/23 Goldman Sachs Erasca initiated with a Buy at Goldman Sachs 02/03/23 Morgan Stanley Erasca upgraded to Overweight from Equal Weight at Morgan Stanley IMRX Immuneering $6.95 / -1.23 (-15.04%) 04/19/23 Mizuho Immuneering upgraded to Buy from Neutral at Mizuho 04/19/23 Morgan Stanley Immuneering upgraded to Equal Weight from Underweight at Morgan Stanley 04/18/23 Chardan Immuneering price target raised to $22 from $18 at Chardan 03/29/23 Mizuho Immuneering initiated with a Neutral at Mizuho VSTM Verastem / + 05/10/23 H.C. Wainwright Verastem price target lowered to $2 from $3 at H.C. Wainwright 03/29/23 Mizuho Verastem initiated with a Neutral at Mizuho 11/07/22 H.C. Wainwright Verastem price target lowered to $3 from $5 at H.C. Wainwright 10/05/22 BTIG Verastem price target lowered to $5 from $8 at BTIG MRK Merck $113.28 / -1.175 (-1.03%) 05/10/23 Jefferies Prometheus downgraded to Hold from Buy at Jefferies 05/01/23 Barclays Merck price target raised to $130 from $128 at Barclays 04/18/23 Wells Fargo Prometheus downgraded to Equal Weight from Overweight at Wells Fargo 04/18/23 RBC Capital Prometheus downgraded to Sector Perform from Outperform at RBC Capital INCY Incyte $65.11 / +0.715 (+1.11%) 05/04/23 JMP Securities Incyte price target lowered to $93 from $113 at JMP Securities 05/04/23 BofA Incyte downgraded to Neutral at BofA on long-term value uncertainty 05/04/23 BofA Incyte downgraded to Neutral from Buy at BofA 05/03/23 BMO Capital Incyte price target lowered to $70 from $75 at BMO Capital EFTR eFfector Therapeutics / + LPTX Leap Therapeutics / + 03/17/23 Piper Sandler Leap Therapeutics news 'disappointing at first glance,' says Piper Sandler 03/17/23 Mizuho Leap Therapeutics price target lowered to $2 from $3 at Mizuho 01/27/23 Mizuho Leap Therapeutics price target lowered to $3 from $6 at Mizuho 01/17/23 Piper Sandler Leap Therapeutics price target lowered to $3 from $4 at Piper Sandler RCUS Arcus Biosciences $18.06 / -0.08 (-0.44%) 03/09/23 Citi Arcus Biosciences price target lowered to $40 from $42 at Citi 12/21/22 Citi Arcus Biosciences selloff a buying opportunity, says Citi 12/21/22 Barclays Arcus Biosciences price target lowered to $36 from $60 at Barclays 12/20/22 Citi Arcus Biosciences price target raised to $42 from $37 at Citi CRVS Corvus Pharmaceuticals $3.09 / -0.28 (-8.31%) 05/09/23 Cantor Fitzgerald Corvus Pharmaceuticals price target raised to $4 from $2 at Cantor Fitzgerald 10/07/22 Ladenburg Corvus Pharmaceuticals initiated with a Buy at Ladenburg 08/09/22 Cantor Fitzgerald Corvus Pharmaceuticals price target lowered to $4 from $8 at Cantor Fitzgerald VSTM RCUS MRK LPTX INCY ERAS EFTR CRVS VSTM Verastem / + 05/09/23 Verastem reports Q1 EPS (9c), consensus (8c) 03/14/23 Verastem reports Q4 EPS (8c), consensus (10c) RCUS Arcus Biosciences $18.06 / -0.08 (-0.44%) 05/09/23 Arcus Biosciences reports Q1 EPS ($1.09), consensus ($1.16) 02/28/23 Arcus Biosciences reports Q4 EPS (93c), consensus ($1.07) MRK Merck $113.28 / -1.175 (-1.03%) 04/27/23 Merck narrows FY23 revenue view to $57.7B-$58.9B from $57.2B-$58.7B 04/27/23 Merck reports Q1 adjusted EPS $1.40, consensus $1.32 04/26/23 Notable companies reporting before tomorrow's open LPTX Leap Therapeutics / + 05/15/23 Leap Therapeutics reports Q1 EPS (32c), consensus (10c) 03/24/23 Leap Therapeutics reports Q4 EPS (11c), consensus (11c) INCY Incyte $65.11 / +0.715 (+1.11%) 05/02/23 Incyte reports Q1 EPS 37c, consensus 75c 02/07/23 Incyte reports Q4 EPS 62c, consensus 58c 02/06/23 Notable companies reporting before tomorrow's open ERAS Erasca $3.00 / +0.075 (+2.57%) 05/15/23 Erasca reports Q1 EPS (22c), consensus (31c) 03/23/23 Erasca reports Q4 EPS ($1.06) vs. (26c) last year EFTR eFfector Therapeutics / + 05/09/23 eFfector Therapeutics reports Q1 EPS (24c), consensus (14c) 03/08/23 eFfector Therapeutics reports Q4 EPS (22c), consensus (24c) CRVS Corvus Pharmaceuticals $3.09 / -0.28 (-8.31%) 05/08/23 Corvus Pharmaceuticals reports Q1 EPS (17c), consensus (16c) 18 Apr 09 Dec MRK MRK Merck $113.28 / -1.175 (-1.03%) 02/27/23 Pfizer in talks to buy Seagen in deal that may be valued at over $30B, WSJ says 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 01/11/23 Merck, Pfizer rebuff China's efforts to cut Covid drug prices, Bloomberg says 12/30/22 Merck's Covid treatment gets conditional approval in China, Reuters reports VSTM RCUS MRK LPTX INCY ERAS VSTM Verastem / + 03/14/23 Fly Intel: After-Hours Movers RCUS Arcus Biosciences $18.06 / -0.08 (-0.44%) 12/20/22 What You Missed On Wall Street On Tuesday 12/20/22 What You Missed On Wall Street This Morning 12/19/22 Fly Intel: After-Hours Movers 11/30/22 Biotech Alert: Searches spiking for these stocks today MRK Merck $113.28 / -1.175 (-1.03%) 05/16/23 What You Missed On Wall Street On Tuesday 04/27/23 Fly Intel: Pre-market Movers 04/19/23 Biotech Alert: Searches spiking for these stocks today 04/17/23 What You Missed On Wall Street On Monday LPTX Leap Therapeutics / + 05/19/23 Biotech Alert: Searches spiking for these stocks today 03/24/23 What You Missed On Wall Street On Friday 03/24/23 What You Missed On Wall Street This Morning INCY Incyte $65.11 / +0.715 (+1.11%) 05/05/23 Biotech Alert: Searches spiking for these stocks today 05/04/23 Biotech Alert: Searches spiking for these stocks today 05/02/23 Fly Intel: Pre-market Movers 04/10/23 What You Missed On Wall Street On Monday ERAS Erasca $3.00 / +0.075 (+2.57%) 03/23/23 Fly Intel: After-Hours Movers 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/09/22 What You Missed On Wall Street On Friday 12/09/22 What You Missed On Wall Street This Morning 05/24/23 Biotechnology 18:00 Today Biotechnology--Pre-ASCO Reception 06/09/23 Biotechnology 06/12/23 Biotech/Biopharma 00:00 Today 2023 ASCO Annual Meeting 05/31/23 Verastem - VSTM 08/01/23 Merck - MRK 05/24/23 Immuneering 06/14/23 Incyte Corporation 06/14/23 Immuneering Corp. 06/15/23 Arcus Biosciences, Inc. 06/15/23 Corvus Pharmaceuticals, Inc. 06/16/23 Leap Therapeutics, Inc. 06/22/23 Erasca, Inc. 06/22/23 eFFECTOR Therapeutics Inc MRK MRK Merck $113.28 / -1.175 (-1.03%) 04/25/23 Merck call volume above normal and directionally bullish 04/17/23 Unusually active option classes on open April 17th 03/10/23 Early notable gainers among liquid option names on March 10th 01/10/23 Largest borrow rate increases among liquid names

On The Fly

News and insights, exclusive to thefly.com

11:00	Biotech Alert: Searches spiking for these stocks today»
10:28	Here's What You Missed in Crypto This Week»
09:38	Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations»
08:59	Fly Intel: Pre-market Movers»
19:09	Fly Intel: After-Hours Movers»

View all On The Fly Stories »

Upcoming
Events (10)

A ...	2023 ASCO Annual Meeting
AUTL ...	Truist Hosted Company Events at 2023 ASCO Annual Meeting
LICY	Li-Cycle
MXL	MaxLinear
GERN	Geron
	Healthcare
TERN	Biotechnology--Reception
	Consumer Retail & Lifestyle Brands
YJ	Yunji - YJ
WDH	Waterdrop - WDH

View all of today’s events »

Today’s
Syndicate (1)

MKSI	Spot Secondary

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial